Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma

Cited by (1,021)

Items 701–800 of 1,021

1. Combining Immune Checkpoint Inhibitors with Anti-Angiogenic Agents
   Paola Ciciola, Priscilla Cascetta, Cataldo Bianco, Luigi Formisano, Roberto Bianco · 2020 · Journal of Clinical Medicine
2. Survival of patients with advanced metastatic melanoma: The impact of MAP kinase pathway inhibition and immune checkpoint inhibition - Update 2019
   Selma Ugurel, Joachim Röhmel, Paolo A. Ascierto, Jürgen Christian Becker, Keith T. Flaherty, Jean‐Jacques Grob, Axel Hauschild, James Larkin, Elisabeth Livingstone, Georgina Venetia Long et al. · 2020 · European Journal of Cancer
3. Metastatic melanoma to the liver: A contemporary and comprehensive review of surgical, systemic, and regional therapeutic options
   Sanjiv S. Agarwala, Alexander M.M. Eggermont, Steven J O'Day, Jonathan S. Zager · 2013 · Cancer
4. Safety and efficacy of ipilimumab to treat advanced melanoma in the setting of liver transplantation
   Morales, Rita E, Shoushtari, Alexander N, Walsh, Michelle M, Grewal, Priya, Lipson, Evan J, Carvajal, Richard D · 2015 · Journal for ImmunoTherapy of Cancer
5. Tumour‐infiltrating lymphocytes and expression of programmed death ligand 1 (PD‐L1) in melanoma brain metastases
   Anna Sophie Berghoff, Gerda Ricken, Georg Widhalm, Orsolya Rajky, Karin Ute Dieckmann, Peter Birner, Rupert Bartsch, Christoph Höeller, Matthias Preusser · 2014 · Histopathology
6. Immunologic checkpoints in cancer therapy: focus on the programmed death-1 (PD-1) receptor pathway
   Michael A. Postow, Parisa Momtaz · 2014 · Pharmacogenomics and Personalized Medicine
7. Immunotherapies for non-small-cell lung cancer and mesothelioma
   Anish Thomas, Raffit Hassan · 2012 · The Lancet Oncology
8. Toxicity management of immunotherapy for patients with metastatic melanoma
   Helena Linardou, Helen J Gogas · 2016 · Annals of Translational Medicine
9. Analysis of Spontaneous Tumor-Specific CD4 T-cell Immunity in Lung Cancer Using Promiscuous HLA-DR Telomerase-Derived Epitopes: Potential Synergistic Effect with Chemotherapy Response
   Yann Godet, Elizabeth Fabre, Magalie Dosset, Michele Lamuraglia, Émeline Levionnois, Patrice Ravel, Nadine Benhamouda, Aurélie Cazes, Françoise Le Pimpec‐Barthes, Béatrice Gaugler et al. · 2012 · Clinical Cancer Research
10. PD-1, PD-L1 (B7-H1) and Tumor-Site Immune Modulation Therapy: The Historical Perspective
    Jun Wang, Ruirong Yuan, Wenru Song, Jingwei Sun, Delong Liu, Zihai Li · 2017 · Journal of Hematology & Oncology
11. Tumor-Localized Secretion of Soluble PD1 Enhances Oncolytic Virotherapy
    Mee Y. Bartee, Katherine M. Dunlap, Eric Bartee · 2017 · Cancer Research
12. Modulation of temozolomide dose differentially affects T-cell response to immune checkpoint inhibition
    Aida Karachi, Changlin Yang, Farhad Dastmalchi, Elias Joseph Sayour, Jianping Huang, Hassan Azari, Yu Long, Catherine Flores, Duane A. Mitchell, Maryam Rahman · 2019 · Neuro-Oncology
13. Peripheral CD8 effector-memory type 1 T-cells correlate with outcome in ipilimumab-treated stage IV melanoma patients
    Wistuba-Hamprecht, Kilian, Martens, Alexander, Heubach, Florian, Romano, Emanuela, Geukes Foppen, Marnix, Yuan, Jianda, Postow, Michael, Wong, Phillip, Mallardo, Domenico, Schilling, Bastian et al. · 2017 · European Journal of Cancer
14. Immuno-oncology Combinations: A Review of Clinical Experience and Future Prospects
    Scott Joseph Antonia, James Larkin, Paolo A. Ascierto · 2014 · Clinical Cancer Research
15. Adjuvant bevacizumab in patients with melanoma at high risk of recurrence (AVAST-M): preplanned interim results from a multicentre, open-label, randomised controlled phase 3 study
    Pippa G. Corrie, Andrea Marshall, Janet Dunn, Mark Ross Middleton, Paul Nathan, Martin Eric Gore, Neville G. P. Davidson, Steve Nicholson, Charles Gerald Kelly, Maria Marples et al. · 2014 · The Lancet Oncology
16. Thermal Ablative Therapies and Immune Checkpoint Modulation: Can Locoregional Approaches Effect a Systemic Response?
    Amol M. Mehta, Rahmi Öklü, Rahul A. Sheth · 2016 · Gastroenterology Research and Practice
17. Talimogene Laherparepvec for the Treatment of Advanced Melanoma
    Patrick Alexander Ott, Frank Stephen Hodi · 2016 · Clinical Cancer Research
18. Combinatorial Cancer Immunotherapies
    Matthew David Hellmann, Claire Frances Friedman, Jedd D. Wolchok · 2016 · Advances in immunology
19. The emerging role of immune checkpoint inhibition in malignant lymphoma
    Ida Hude, Stephanie Sasse, Andreas Engert, Paul Jan Bröckelmann · 2016 · Haematologica
20. Challenging resistance mechanisms to therapies for metastatic melanoma
    Lucio Tentori, Pedro Miguel Lacal, Grazia Graziani · 2013 · Trends in Pharmacological Sciences
21. CD73-Generated Adenosine: Orchestrating the Tumor-Stroma Interplay to Promote Cancer Growth
    Bertrand Allard, Martin Turcotte, John Stagg · 2012 · BioMed Research International
22. Clinical Impact of Checkpoint Inhibitors as Novel Cancer Therapies
    Kent C. Shih, Hendrik‐Tobias Arkenau, Jeffrey R. Infante · 2014 · Drugs
23. Immuno-oncology combinations: raising the tail of the survival curve
    Samuel J. Harris, Samuel J. Harris, Jessica S. Brown, Juanita Suzanne Lopez, Timothy Anthony Yap, Jessica S. Brown, Juanita Suzanne Lopez, Timothy Anthony Yap · 2016 · Cancer Biology and Medicine
24. Novel immune check point inhibiting antibodies in cancer therapy—Opportunities and challenges
    Yael Diesendruck, Itai Benhar · 2017 · Drug Resistance Updates
25. The use of immunotherapy in the treatment of melanoma
    Tala Achkar, Ahmad A. Tarhini · 2017 · Journal of Hematology & Oncology
26. Comparative Analysis of Durable Responses on Immune Checkpoint Inhibitors Versus Other Systemic Therapies: A Pooled Analysis of Phase III Trials
    Elvire Pons Tostivint, Aurélien Latouche, Pauline Vaflard, Francesco Ricci, Delphine Loirat, S. Hescot, Marie‐Paule Sablin, Roman Rouzier, Maud T Kamal, Claire Morel et al. · 2019 · JCO Precision Oncology
27. Vemurafenib
    Anant Sharma, Sachin R. Shah, Henrik Illum, Jonathan E. Dowell · 2012 · Drugs
28. The rapidly evolving therapies for advanced melanoma—Towards immunotherapy, molecular targeted therapy, and beyond
    Ziqiang Zhu, Wei Liu, Vladimir K. Gotlieb · 2015 · Critical Reviews in Oncology/Hematology
29. Combinatorial approach to cancer immunotherapy: strength in numbers
    Anna E. Vilgelm, Douglas Buckner Johnson, Ann J. Richmond · 2016 · Journal of Leukocyte Biology
30. Adverse Renal Effects of Novel Molecular Oncologic Targeted Therapies: A Narrative Review
    Kenar D. Jhaveri, Rimda Wanchoo, Vipulbhai Sakhiya, Daniel W. Ross, Steven N. Fishbane · 2016 · Kidney International Reports
31. Contemporary experience with high-dose interleukin-2 therapy and impact on survival in patients with metastatic melanoma and metastatic renal cell carcinoma
    Ajjai Shivaram Alva, Gregory A. Daniels, Michael K. Wong, Howard L. Kaufman, Michael Andrew Morse, David F. McDermott, Joseph I. Clark, Sanjiv S. Agarwala, Gerald P. Miletello, Theodore F. Logan et al. · 2016 · Cancer Immunology Immunotherapy
32. Dutch Melanoma Treatment Registry: Quality assurance in the care of patients with metastatic melanoma in the Netherlands
    Anouk Jochems, Maartje Gisele Schouwenburg, Brenda Leeneman, Margreet G. Franken, Alfons J.M. van den Eertwegh, John B.A.G. Haanen, Hans A. J. Gelderblom, Carin A. Uyl‐de Groot, Maureen J.B. Aarts, Franchette W.P.J. van den Berkmortel et al. · 2016 · European Journal of Cancer
33. Health-related quality of life with adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): secondary outcomes of a multinational, randomised, double-blind, phase 3 trial
    Corneel Coens, Stefan Suciu, Vanna Chiarion‐Sileni, Jean‐Jacques Grob, Reinhard Dummer, Jedd D. Wolchok, Henrik Schmidt, Omid Hamid, Caroline Robert, Paolo A. Ascierto et al. · 2017 · The Lancet Oncology
34. Combination of Ipilimumab and Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes for Patients with Metastatic Melanoma
    John E. Mullinax, MacLean S. Hall, Sangeetha Prabhakaran, Jeffrey S. Weber, Nikhil I. Khushalani, Zeynep Eroglu, Andrew Scott Brohl, Joseph Markowitz, Erica Bruce Royster, Allison D. Richards et al. · 2018 · Frontiers in Oncology
35. Using virally expressed melanoma cDNA libraries to identify tumor-associated antigens that cure melanoma
    José S. Pulido, Timothy J. Kottke, Jill Thompson, Feorillo Galivo, Phonphimon Wongthida, Rosa María Díaz, Diana M. Rommelfanger, Elizabeth J. Ilett, Larry R. Pease, Hardev Pandha et al. · 2012 · Nature Biotechnology
36. Targeting Oncogenic Drivers and the Immune System in Melanoma
    Grant A. McArthur, Antoni Ribas · 2012 · Journal of Clinical Oncology
37. Challenges of phase 1 clinical trials evaluating immune checkpoint-targeted antibodies
    Sophie C. Postel-Vinay, Sandrine Aspeslagh, Émilie Lanoy, Caroline Robert, Jean‐Charles Soria, Aurélien Marabelle · 2015 · Annals of Oncology
38. A phase 2 study of tremelimumab in patients with advanced uveal melanoma
    Anthony Michael Joshua, Jose Gerard Monzon, Catalin Liviu Dragos Mihalcioiu, David Hogg, Michael Smylie, Tina Cheng · 2015 · Melanoma Research
39. Clinical experience with CTLA-4 blockade for cancer immunotherapy: From the monospecific monoclonal antibody ipilimumab to probodies and bispecific molecules targeting the tumor microenvironment
    Lucia Lisi, Pedro Miguel Lacal, Maria Martire, Pierluigi Navarra, Grazia Graziani · 2021 · Pharmacological Research
40. T Cells in Colorectal Cancer: Unravelling the Function of Different T Cell Subsets in the Tumor Microenvironment
    Ziwen Zheng, Thomas Wieder, Bernhard Mauerer, Luisa Schäfer, Rebecca Kesselring, Heidi Braumüller · 2023 · International Journal of Molecular Sciences
41. Durable responses and reversible toxicity of high-dose interleukin-2 treatment of melanoma and renal cancer in a Community Hospital Biotherapy Program
    Roxanne Payne, Lyn A. Glenn, Helena Maria Hoen, Beverley Richards, John W. Smith, Robert B. Lufkin, Todd S. Crocenzi, Walter John Urba, Brendan D. Curti · 2014 · Journal for ImmunoTherapy of Cancer
42. In Situ Vaccination for the Treatment of Cancer
    Linda Hammerich, Nina Bhardwaj, Holbrook E K Kohrt, Joshua Brody · 2016 · Immunotherapy
43. COX-2 expression positively correlates with PD-L1 expression in human melanoma cells
    Botti, Gerardo, Fratangelo, Federica, Cerrone, Margherita, Liguori, Giuseppina, Cantile, Monica, Anniciello, Anna Maria, Scala, Stefania, D’Alterio, Crescenzo, Trimarco, Chiara, Ianaro, Angela et al. · 2017 · Journal of Translational Medicine
44. Clinical evaluation of compounds targeting PD-1/PD-L1 pathway for cancer immunotherapy
    Jing Lü, Linda Lee-Gabel, Michelle C Nadeau, Thomas M. Ferencz, Scott A. Soefje · 2014 · Journal of Oncology Pharmacy Practice
45. Antibody Positron Emission Tomography Imaging in Anticancer Drug Development
    Laetitia E. Lamberts, Simon Peter Williams, Anton G.T. Terwisscha van Scheltinga, Marjolijn N. Lub–de Hooge, Carolien P. Schröder, Jourik A. Gietema, Adrienne H. Brouwers, Elisabeth G.E. de Vries · 2015 · Journal of Clinical Oncology
46. Programmed death-ligand 1 (PD-L1) characterization of circulating tumor cells (CTCs) in muscle invasive and metastatic bladder cancer patients
    Archana Anantharaman, Terence W. Friedlander, David M. Lu, Rachel Krupa, Gayatri Premasekharan, Jeffrey Hough, Matthew Edwards, Rosa Paz, Karla J. Lindquist, Ryon P. Graf et al. · 2016 · BMC Cancer
47. The majority of patients with metastatic melanoma are not represented in pivotal phase III immunotherapy trials
    Marco Donia, Marie Louise Kimper-Karl, Katrine Lundby Høyer, Lars Bastholt, Henrik Schmidt, Inge Marie Svane · 2017 · European Journal of Cancer
48. Development of Novel ImmunoPET Tracers to Image Human PD-1 Checkpoint Expression on Tumor-Infiltrating Lymphocytes in a Humanized Mouse Model
    Arutselvan Natarajan, Aaron T. Mayer, Robert E. Reeves, Claude M. Nagamine, Sanjiv Sam Gambhir · 2017 · Molecular Imaging and Biology
49. Life expectancy difference and life expectancy ratio: two measures of treatment effects in randomised trials with non-proportional hazards
    Hakim‐Moulay Dehbi, Patrick J Royston, Allan K. Hackshaw · 2017 · BMJ
50. Immune cell profiling in cancer: molecular approaches to cell-specific identification
    Yasmin A. Lyons, Sherry Y. Wu, Willem W. Overwijk, Keith Baggerly, Anil K. Sood · 2017 · npj Precision Oncology
51. NKG2A, a New Kid on the Immune Checkpoint Block
    John B.A.G. Haanen, Vincenzo Cerundolo · 2018 · Cell
52. European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment – Update 2024
    Claus Garbe, Teresa Maria Santos Amaral, Ketty Peris, Axel Hauschild, Petr Arenberger, Nicole Basset‐Séguin, Lars Bastholt, Veronique A. Bataille, Liève Brochez, V. del Mármol et al. · 2024 · European Journal of Cancer
53. The Immunocytokine L19–IL2 Eradicates Cancer When Used in Combination with CTLA-4 Blockade or with L19-TNF
    Kathrin Schwager, Teresa Hemmerle, David Aebischer, Dario Neri · 2012 · Journal of Investigative Dermatology
54. A tale of two approaches: complementary mechanisms of cytotoxic and targeted therapy resistance may inform next-generation cancer treatments
    Kenta Masui, Beatrice Gini, J. Wykosky, Ciro Zanca, Paul S. Mischel, Frank B. Furnari, Webster K. Cavenee · 2013 · Carcinogenesis
55. Chemotherapy response of spontaneous mammary tumors is independent of the adaptive immune system
    Metamia Ciampricotti, Cheei‐Sing Hau, Chris W. Doornebal, Jos Jonkers, Karin E. de Visser · 2012 · Nature Medicine
56. Model‐based clinical pharmacology profiling of ipilimumab in patients with advanced melanoma
    Yan Feng, Eric Masson, David Dai, Susan M. Parker, David Berman, Amit Roy · 2014 · British Journal of Clinical Pharmacology
57. Phase I trial of tremelimumab in combination with short-term androgen deprivation in patients with PSA-recurrent prostate cancer
    Douglas G. McNeel, Heath A. Smith, Jens C. Eickhoff, Joshua Michael Lang, Mary Jane Staab, George Wilding, Glenn Liu · 2011 · Cancer Immunology Immunotherapy
58. Metronomic chemotherapy for cancer treatment: a decade of clinical studies
    Adriana Romiti, Maria Christina Cox, Ida Sarcina, Roberta Di Rocco, Chiara D’Antonio, Viola Barucca, Paolo Marchetti · 2013 · Cancer Chemotherapy and Pharmacology
59. Vaccination with mRNA-Electroporated Dendritic Cells Induces Robust Tumor Antigen-Specific CD4+ and CD8+ T Cells Responses in Stage III and IV Melanoma Patients
    Erik H.J.G. Aarntzen, Gerty Schreibelt, Kalijn F. Bol, Willem Joost Lesterhuis, Alexandra J. Croockewit, Johannes H.W. de Wilt, Michelle M. van Rossum, Willeke A.M. Blokx, Joannes F.M. Jacobs, Tjitske Duiveman‐de Boer et al. · 2012 · Clinical Cancer Research
60. Turning Tumors into Vaccines: Co-opting the Innate Immune System
    Jasper G. van den Boorn, Gunther Hartmann · 2013 · Immunity
61. Sequential Treatment with Ipilimumab and BRAF Inhibitors in Patients With Metastatic Melanoma: Data From the Italian Cohort of the Ipilimumab Expanded Access Program
    Paolo A. Ascierto, Ester Simeone, Vanna Chiarion‐Sileni, Michele Del Vecchio, Paolo Marchetti, Gian Carlo Antonini Cappellini, Ruggero Ridolfi, Francesco De Rosa, Francesco Cognetti, Virginia Ferraresi et al. · 2014 · Cancer Investigation
62. Inhibition of both BRAF and MEK in BRAFV600E mutant melanoma restores compromised dendritic cell (DC) function while having differential direct effects on DC properties
    Patrick Alexander Ott, Trevor Henry, Sonja Jimenez Baranda, Davor Frleta, Olivier Manches, Dusan Bogunovic, Nina Bhardwaj · 2013 · Cancer Immunology Immunotherapy
63. Limitations and opportunities for immune checkpoint inhibitors in pediatric malignancies
    Jeong Ah Park, Nai‐Kong V. Cheung · 2017 · Cancer Treatment Reviews
64. Pediatric Cancer Immunotherapy: Opportunities and Challenges
    Mary Frances Wedekind, Nicholas L. Denton, Chun‐Yu Chen, Timothy P. Cripe · 2018 · Pediatric Drugs
65. Potential immune escape mechanisms underlying the distinct clinical outcome of immune checkpoint blockades in small cell lung cancer
    Yaru Tian, Xiaoyang Zhai, Anqin Han, Hui Zhu, Jinming Yu · 2019 · Journal of Hematology & Oncology
66. Surgery for Distant Melanoma Metastasis
    Anna Mary Leung, Danielle M. Hari, Donald L. Morton · 2012 · The Cancer Journal
67. A Phase II, Randomized, Double-blind, Placebo-controlled Multicenter Trial of Endostar in Patients With Metastatic Melanoma
    Chuanliang Cui, Lili Mao, Zhihong Chi, Lu Si, Xinan Sheng, Yan Kong, Siming Li, Bin Lian, Kangsheng Gu, Min Tao et al. · 2013 · Molecular Therapy
68. Systemic Immunotherapy of Non-Muscle Invasive Mouse Bladder Cancer with Avelumab, an Anti–PD-L1 Immune Checkpoint Inhibitor
    Amanda J. Vandeveer, Jonathan K. Fallon, Robert Tighe, Helen Sabzevari, Jeffrey Schlom, John W. Greiner · 2016 · Cancer Immunology Research
69. Efficacy and safety of anti-PD-1 and anti-PD-1 combined with anti-CTLA-4 immunotherapy to advanced melanoma
    Chunyan Hao, Jinhui Tian, Huiling Liu, Fei Li, Hongxia Niu, Bingdong Zhu · 2017 · Medicine
70. Targeting innate sensing in the tumor microenvironment to improve immunotherapy
    Zhida Liu, Chuanhui Han, Yang‐Xin Fu · 2019 · Cellular and Molecular Immunology
71. Ultraviolet Radiation and Melanomagenesis: From Mechanism to Immunotherapy
    Xiaoying Sun, Na Zhang, Chengqian Yin, Bo Zhu, Xin Li · 2020 · Frontiers in Oncology
72. Immunotherapy discontinuation — how, and when? Data from melanoma as a paradigm
    Caroline Robert, Aurélien Marabelle, Hugo Herrscher, Caroline Caramella, Pascal Rouby, Karim S. Fizazi, Benjamin Besse · 2020 · Nature Reviews Clinical Oncology
73. Electrochemotherapy for disseminated superficial metastases from malignant melanoma
    Luca Giovanni Campana, Sara Valpione, Simone Mocellin M. D, Rajeswari Sundararajan, Elisa Granziera, Leonardo Sartore, Vanna Chiarion‐Sileni, Carlo Riccardo Rossi · 2012 · British journal of surgery
74. Survivorship in Immune Therapy: Assessing Chronic Immune Toxicities, Health Outcomes, and Functional Status among Long-term Ipilimumab Survivors at a Single Referral Center
    Johnson, Douglas B., Friedman, Debra L., Berry, Elizabeth, Decker, Ilka, Ye, Fei, Zhao, Shilin, Morgans, Alicia K., Puzanov, Igor, Sosman, Jeffrey A., Lovly, Christine M. · 2015 · Cancer Immunology Research
75. Oncolytic and Immunotherapeutic Vaccinia Induces Antibody-Mediated Complement-Dependent Cancer Cell Lysis in Humans
    Mi Kyung Kim, Caroline J. Breitbach, Anne Moon, Jeong Heo, Yu Kyoung Lee, Mong Cho, Jun Woo Lee, Seong-Geun Kim, Dae Hwan Kang, John Cameron Bell et al. · 2013 · Science Translational Medicine
76. Efficacy and safety of ipilimumab in elderly patients with pretreated advanced melanoma treated at Italian centres through the expanded access programme
    Vanna Chiarion‐Sileni, Jacopo Pigozzo, Paolo A. Ascierto, Antonio Maria Grimaldi, Michele Maio, Lorenza Di Guardo, Paolo Marchetti, Francesco De Rosa, Carmen M. A. Nuzzo, Alessandro Testori et al. · 2014 · Journal of Experimental & Clinical Cancer Research
77. Combined Immunostimulatory Monoclonal Antibodies Extend Survival in an Aggressive Transgenic Hepatocellular Carcinoma Mouse Model
    Aizea Morales‐Kastresana, Miguel F. Sanmamed, Inmaculada Rodríguez, Asís Palazón, Iván Martínez‐Forero, Sara Labiano, Sandra Hervás‐Stubbs, Bruno Sangro, Carmen Ochoa, Ana Rouzaut et al. · 2013 · Clinical Cancer Research
78. Combined treatment with dabrafenib and trametinib with immune-stimulating antibodies for BRAF mutant melanoma
    Blanca Homet Moreno, Stephen Mok, Begonya Comin-Anduix, Siwen Hu‐Lieskovan, Antoni Ribas · 2015 · OncoImmunology
79. Acute rhabdomyolysis with severe polymyositis following ipilimumab-nivolumab treatment in a cancer patient with elevated anti-striated muscle antibody
    Mehmet Asım Bilen, Sumit Kumar Subudhi, Jianjun Gao, Nizar M. Tannir, Shi‐Ming Tu, Padmanee Sharma · 2016 · Journal for ImmunoTherapy of Cancer
80. Expression of lymphocyte immunoregulatory biomarkers in bone and soft-tissue sarcomas
    Amanda R. Dancsok, Nokitaka Setsu, Dongxia Gao, Jean‐Yves Blay, David Morgan Thomas, Robert G. Maki, Torsten O. Nielsen, Elizabeth G. Demicco · 2019 · Modern Pathology
81. Anti-CTLA-4 nanobody as a promising approach in cancer immunotherapy
    Mehregan Babamohamadi, Nastaran Mohammadi, Elham Faryadi, Maryam Haddadi, Amirhossein Merati, Farbod Ghobadinezhad, Roshanak Amirian, Zhila Izadi, Jamshid Hadjati · 2024 · Cell Death and Disease
82. Fluctuations in routine blood count might signal severe immune-related adverse events in melanoma patients treated with nivolumab
    Yasuhiro Fujisawa, Koji Yoshino, Atsushi Otsuka, Takeru Funakoshi, Taku Fujimura, Yuki Yamamoto, Hiroo Hata, Masahiko Gosho, Ryota Tanaka, Kei Yamaguchi et al. · 2017 · Journal of Dermatological Science
83. Stemming the Rising Incidence of Melanoma: Calling Prevention to Action
    Jeffrey E. Gershenwald, Gery P. Guy · 2015 · JNCI Journal of the National Cancer Institute
84. Gastrointestinal toxicity of immune checkpoint inhibitors: From mechanisms to management
    Samaan, Mark A., Pavlidis, Polychronis, Papa, Sophie, Powell, Nick, Irving, Peter M. · 2018 · Nature Reviews Gastroenterology & Hepatology
85. DNA fusion-gene vaccination in patients with prostate cancer induces high-frequency CD8+ T-cell responses and increases PSA doubling time
    Lindsey Chudley, Katy J. McCann, Ann Mander, Torunn Elisabeth Tjelle, Juan J. Campos-Pérez, Rosemary Godeseth, Antonia Creak, James Dobbyn, Bernadette Johnson, Paul Bass et al. · 2012 · Cancer Immunology Immunotherapy
86. Immunotherapy for Brain Cancer: Recent Progress and Future Promise
    Christopher Mitchell Jackson, Michael K. Lim, Charles G. Drake · 2014 · Clinical Cancer Research
87. Immune Profiling of Adenoid Cystic Carcinoma: PD-L2 Expression and Associations with Tumor-Infiltrating Lymphocytes
    Vishwajith Sridharan, Evisa Gjini, Xiaoyun Liao, Nicole Grace Chau, Robert I. Haddad, Mariano Severgnini, Peter S. Hammerman, Adel K. El‐Naggar, Gordon James Freeman, Frank Stephen Hodi et al. · 2016 · Cancer Immunology Research
88. Coinhibitory molecule PD-1 as a potential target for the immunotherapy of multiple myeloma
    Djordje Atanackovic, Tim Luetkens, Nicolaus Martin Kröger · 2013 · Leukemia
89. Immune Checkpoint Modulation for Non–Small Cell Lung Cancer
    Jean‐Charles Soria, Aurélien Marabelle, Julie Renee Brahmer, Scott N. Gettinger · 2015 · Clinical Cancer Research
90. Renal complications of immune checkpoint blockade
    Naoka Murakami, Shveta S. Motwani, Leonardo V. Riella · 2016 · Current Problems in Cancer
91. Biological mechanisms of immune escape and implications for immunotherapy in head and neck squamous cell carcinoma
    Jennifer D. Moy, Jessica M. Moskovitz, Robert Louis Ferris · 2017 · European Journal of Cancer
92. Immunotherapy for colorectal cancer: where are we heading?
    Debora Basile, Silvio Ken Garattini, Marta Bonotto, Elena Ongaro, Mariaelena Casagrande, Monica Cattaneo, Valentina Fanotto, Elisa De Carlo, Fotios Loupakis, Federica Urbano et al. · 2017 · Expert Opinion on Biological Therapy
93. Epigenetic Mechanisms of Resistance to Immune Checkpoint Inhibitors
    Alexandre Perrier, Audrey Didelot, Pierre Laurent‐Puig, Hélène Blons, Simon Garinet · 2020 · Biomolecules
94. A randomized, controlled phase III trial of nab-Paclitaxel versus dacarbazine in chemotherapy-naïve patients with metastatic melanoma
    E. M. Hersh, Michele Del Vecchio, Michael Paul Brown, Richard F. Kefford, Carmen Loquai, Alessandro Testori, Shailender Bhatia, Ralf Gutzmer, Robert Martin Conry, Andrew Mark Haydon et al. · 2015 · Annals of Oncology
95. Targeting immune checkpoints in unresectable metastatic cutaneous melanoma: a systematic review and meta‐analysis of anti‐CTLA‐4 and anti‐PD‐1 agents trials
    Seongseok Yun, Nicole D. Vincelette, Myke R. Green, Andrea E. Wahner Hendrickson, Ivo L Abraham · 2016 · Cancer Medicine
96. Immunotherapy in gastric cancer
    Satoko Matsueda · 2014 · World Journal of Gastroenterology
97. Imaging of T-cells and their responses during anti-cancer immunotherapy
    Massis Krekorian, Gilbert O. Fruhwirth, Mangala Srinivas, Carl Gustav Figdor, Sandra Heskamp, Timothy Howard Witney, Erik H.J.G. Aarntzen · 2019 · Theranostics
98. Targeting the NF-κB pathway as a potential regulator of immune checkpoints in cancer immunotherapy
    Nasim Ebrahimi, Al‐Hasnawi Rasool Riyadh Abdulwahid, Atena Mansouri, Nasrin Karimi, Rashid Jafardoust Bostani, Sheida Beiranvand, Samaneh Adelian, Roya Khorram, Reza Vafadar, Michael Richard Hamblin et al. · 2024 · Cellular and Molecular Life Sciences
99. A combination trial of vaccine plus ipilimumab in metastatic castration-resistant prostate cancer patients: immune correlates
    Caroline Jochéms, Jo Anne Tucker, Kwong-Yok Tsang, Ravi Amrit Madan, William L. Dahut, David J. Liewehr, Seth M. Steinberg, James L. Gulley, Jeffrey Schlom · 2014 · Cancer Immunology Immunotherapy
100. Rationale for targeting the immune system through checkpoint molecule blockade in the treatment of non-small-cell lung cancer
     Christoph Carl Zielinski, Sylvia Knapp, Céline Mascaux, Fred R. Hirsch · 2013 · Annals of Oncology